Mineralys Therapeutics (MLYS) Cash from Investing Activities (2022 - 2026)

Mineralys Therapeutics has reported Cash from Investing Activities for 5 years, with the latest figure at -$44.9 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 51.61% year-over-year to -$44.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$341.8 million (down 538.03% YoY) and the FY2025 annual result came in at -$389.8 million, down 439.04% from the prior year.
• Cash from Investing Activities improved to -$44.9 million in Q1 2026 per MLYS's latest filing, from -$103.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $83.6 million in Q4 2024 and troughed at -$150.5 million in Q3 2025.
• A 5-year average of -$33.5 million and a median of -$42.9 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 1886.65% in 2024, then tumbled 654.3% in 2025.
• Over 5 years, Cash from Investing Activities stood at $50.0 million in 2022, then plunged by 116.18% to -$8.1 million in 2023, then jumped by 1133.13% to $83.6 million in 2024, then plunged by 223.84% to -$103.5 million in 2025, then soared by 56.57% to -$44.9 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$44.9 million, -$103.5 million, and -$150.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.